7:09 PM
 | 
Jul 27, 2007
 |  BC Extra  |  Company News

FDA posts Tysabri briefing documents

FDA will ask an advisory panel on July 31 whether the label for Tysabri natalizumab from Elan (ELN) and Biogen Idec (BIIB) should be expanded to treat moderate to severe Crohn's disease in patients who have failed or cannot tolerate prior therapy. According to briefing documents released on Friday, panelists at the joint meeting of the Gastrointestinal Drugs and the Drug Safety and Risk Management...

Read the full 320 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >